The Role of the BRCA2 Gene in Susceptibility to Prostate Cancer Revisited

Overview

Journal Cancer Epidemiol Biomarkers Prev

Specialties Biochemistry
Oncology
Public Health

Date 2008 Aug 19

PMID 18708369

Citations 19

Authors

Elaine A Ostrander

Miriam S Udler

Affiliations

Soon will be listed here.

Abstract

Prostate cancer is a genetically complex disease with multiple predisposing factors affecting presentation, progression, and outcome. Epidemiologic studies have long shown an aggregation of breast and prostate cancer in some families. More recently, studies have reported an apparent excess of prostate cancer cases among BRCA2 mutation-carrying families. Additionally, population-based screens of early-onset prostate cancer patients have suggested that the prevalence of deleterious BRCA2 mutations in this group is 1% to 2%, imparting a significantly increased risk of the disease compared with noncarrier cases. However, studies of high-risk prostate cancer families suggest that BRCA2 plays at most a minimal role in these individuals, highlighting the potential genetic heterogeneity of the disease. In this commentary, we review the current literature and hypotheses surrounding the relationship between BRCA2 mutations and susceptibility to prostate cancer and speculate on the potential for involvement of additional genes.

Citing Articles

A Large-Scale Association Study Detects Novel Rare Variants, Risk Genes, Functional Elements, and Polygenic Architecture of Prostate Cancer Susceptibility.

Emami N, Cavazos T, Rashkin S, Cario C, Graff R, Tai C Cancer Res. 2020; 81(7):1695-1703.

PMID: 33293427 PMC: 8137514. DOI: 10.1158/0008-5472.CAN-20-2635.

Cancer Genetics and Therapeutic Opportunities in Urologic Practice.

Adashek J, Leonard A, Roszik J, Menta A, Genovese G, Subbiah V Cancers (Basel). 2020; 12(3).

PMID: 32197306 PMC: 7140104. DOI: 10.3390/cancers12030710.

Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer.

Jafari S, Molavi O, Kahroba H, Hejazi M, Maleki-Dizaji N, Barghi S Cell Mol Life Sci. 2020; 77(19):3693-3710.

PMID: 32006051 PMC: 11104895. DOI: 10.1007/s00018-020-03459-1.

Prevalence and clinical significance of pathogenic germline / mutations in Chinese non-small cell lung cancer patients.

Hu X, Yang D, Li Y, Li L, Wang Y, Chen P Cancer Biol Med. 2019; 16(3):556-564.

PMID: 31565484 PMC: 6743617. DOI: 10.20892/j.issn.2095-3941.2018.0506.

Comparative Secretome Profiling and Mutant Protein Identification in Metastatic Prostate Cancer Cells by Quantitative Mass Spectrometry-based Proteomics.

Kwon O, Jeon J, Sung E, Na A, Kim S, Lee S Cancer Genomics Proteomics. 2018; 15(4):279-290.

PMID: 29976633 PMC: 6070709. DOI: 10.21873/cgp.20086.

References

Salinas C, Kwon E, Carlson C, Koopmeiners J, Feng Z, Karyadi D . Multiple independent genetic variants in the 8q24 region are associated with prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2008; 17(5):1203-13. DOI: 10.1158/1055-9965.EPI-07-2811. View

Slager S, Zarfas K, Brown W, Lange E, McDonnell S, Wojno K . Genome-wide linkage scan for prostate cancer aggressiveness loci using families from the University of Michigan Prostate Cancer Genetics Project. Prostate. 2005; 66(2):173-9. DOI: 10.1002/pros.20332. View

Agalliu I, Kwon E, Zadory D, McIntosh L, Thompson J, Stanford J . Germline mutations in the BRCA2 gene and susceptibility to hereditary prostate cancer. Clin Cancer Res. 2007; 13(3):839-43. DOI: 10.1158/1078-0432.CCR-06-2164. View

Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J . Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995; 378(6559):789-92. DOI: 10.1038/378789a0. View

Loman N, Bladstrom A, Johannsson O, Borg A, Olsson H . Cancer incidence in relatives of a population-based set of cases of early-onset breast cancer with a known BRCA1 and BRCA2 mutation status. Breast Cancer Res. 2003; 5(6):R175-86. PMC: 314401. DOI: 10.1186/bcr632. View

Stanford J, Wicklund K, McKnight B, Daling J, Brawer M . Vasectomy and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 1999; 8(10):881-6. View

Liede A, Karlan B, Narod S . Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol. 2004; 22(4):735-42. DOI: 10.1200/JCO.2004.05.055. View

Carter B, Bova G, Beaty T, Steinberg G, Childs B, Isaacs W . Hereditary prostate cancer: epidemiologic and clinical features. J Urol. 1993; 150(3):797-802. DOI: 10.1016/s0022-5347(17)35617-3. View

Haiman C, Le Marchand L, Yamamato J, Stram D, Sheng X, Kolonel L . A common genetic risk factor for colorectal and prostate cancer. Nat Genet. 2007; 39(8):954-6. PMC: 2391283. DOI: 10.1038/ng2098. View

10.

Sellers T, Potter J, Rich S, Drinkard C, Bostick R, Kushi L . Familial clustering of breast and prostate cancers and risk of postmenopausal breast cancer. J Natl Cancer Inst. 1994; 86(24):1860-5. DOI: 10.1093/jnci/86.24.1860. View

11.

Walsh T, Casadei S, Coats K, Swisher E, Stray S, Higgins J . Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA. 2006; 295(12):1379-88. DOI: 10.1001/jama.295.12.1379. View

12.

Johannesdottir G, Gudmundsson J, Bergthorsson J, Arason A, Agnarsson B, Eiriksdottir G . High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients. Cancer Res. 1996; 56(16):3663-5. View

13.

Sun J, Lange E, Isaacs S, Liu W, Wiley K, Lange L . Chromosome 8q24 risk variants in hereditary and non-hereditary prostate cancer patients. Prostate. 2008; 68(5):489-97. DOI: 10.1002/pros.20695. View

14.

Giusti R, Rutter J, Duray P, Freedman L, Konichezky M, Fisher-Fischbein J . A twofold increase in BRCA mutation related prostate cancer among Ashkenazi Israelis is not associated with distinctive histopathology. J Med Genet. 2003; 40(10):787-92. PMC: 1735297. DOI: 10.1136/jmg.40.10.787. View

15.

Schaid D, Stanford J, McDonnell S, Suuriniemi M, McIntosh L, Karyadi D . Genome-wide linkage scan of prostate cancer Gleason score and confirmation of chromosome 19q. Hum Genet. 2007; 121(6):729-35. DOI: 10.1007/s00439-007-0368-5. View

16.

Erkko H, Xia B, Nikkila J, Schleutker J, Syrjakoski K, Mannermaa A . A recurrent mutation in PALB2 in Finnish cancer families. Nature. 2007; 446(7133):316-9. DOI: 10.1038/nature05609. View

17.

Gross E, Arnold N, Goette J, Schwarz-Boeger U, Kiechle M . A comparison of BRCA1 mutation analysis by direct sequencing, SSCP and DHPLC. Hum Genet. 1999; 105(1-2):72-8. DOI: 10.1007/s004399900092. View

18.

Tulinius H, Olafsdottir G, Sigvaldason H, Arason A, Barkardottir R, Egilsson V . The effect of a single BRCA2 mutation on cancer in Iceland. J Med Genet. 2002; 39(7):457-62. PMC: 1735175. DOI: 10.1136/jmg.39.7.457. View

19.

Stanford J, McDonnell S, Friedrichsen D, Carlson E, Kolb S, Deutsch K . Prostate cancer and genetic susceptibility: a genome scan incorporating disease aggressiveness. Prostate. 2005; 66(3):317-25. DOI: 10.1002/pros.20349. View

20.

Schaid D . The complex genetic epidemiology of prostate cancer. Hum Mol Genet. 2004; 13 Spec No 1:R103-21. DOI: 10.1093/hmg/ddh072. View